alendronate sodium


Also found in: Dictionary, Thesaurus.
Related to alendronate sodium: Risedronate sodium

alendronate sodium

Apo-Alendronate (CA), Co Alendronate (CA), Dom-Alendronate (CA), Fosamax, Gen-Alendronate (CA), Ratio-Alendronate (CA), Sandoz Alendronate

Pharmacologic class: Bisphosphonate

Therapeutic class: Bone-resorption inhibitor

Pregnancy risk category C

Action

Impedes bone resorption by inhibiting osteoclast activity, absorbing calcium phosphate crystal in bone, and directly blocking dissolution of hydroxyapatite crystal of bone

Availability

Tablets: 5 mg, 10 mg, 35 mg, 40 mg, 70 mg

Indications and dosages

Paget's disease of bone (men and women)

Adults: 40 mg P.O. daily for 6 months

Prevention of osteoporosis in postmenopausal women

Adults: 5 mg P.O. daily or 35 mg P.O. once weekly for up to 7 years

Glucocorticoid-induced osteoporosis in men and women

Adults: 5 mg P.O. daily. For postmenopausal women not receiving estrogen, recommended dosage is 10 mg P.O. once daily.

Treatment of osteoporosis in postmenopausal women; treatment to increase bone mass in men with osteoporosis

Adults: 70-mg tablet or 70 mg oral solution P.O. weekly or 10-mg tablet P.O. daily

Contraindications

• Hypersensitivity to drug or its components

• Hypocalcemia

• Esophageal abnormalities such as stricture or achalasia that delay esophageal emptying

• Inability to stand or sit upright for 30 minutes

• Increased risk of aspiration (oral solution)

Precautions

Use cautiously in:

• Severe renal insufficiency (creatinine clearance less than 35 ml/minute), esophageal disease, GI ulcers, gastritis, osteonecrosis of jaw

• pregnant or breastfeeding patients

• children.

Administration

• Give with 6 to 8 oz of water 30 minutes before first food, beverage, or medication of day.

• Don't give at bedtime or before patient arises for the day.

• Don't give food, other beverages, or oral drugs for at least 30 minutes after giving tablets.

• Keep patient upright for at least 30 minutes after giving dose to avoid serious esophageal irritation.

• Follow oral solution with at least 60 ml (2 oz) of water to facilitate gastric emptying.

• Be aware that patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.

• Be aware that aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) may worsen GI upset. Discuss alternative analgesics with prescriber.

Adverse reactions

CNS: headache

CV: hypertension

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, acid regurgitation, esophageal ulcer, flatulence, dyspepsia, abdominal distention, dysphagia

GU: urinary tract infection

Hematologic: anemia

Metabolic: hypomagnesemia, hypophosphatemia, hypokalemia, fluid overload

Musculoskeletal: bone or muscle pain

Skin: rash, redness, photosensitivity

Other: abnormal taste

Interactions

Drug-drug. Antacids, calcium supplements: decreased alendronate absorption

NSAIDs, salicylates: increased risk of GI upset

Ranitidine: increased alendronate effect

Drug-diagnostic tests. Calcium, phosphate: decreased levels

Drug-food. Any food, caffeine (as in coffee, tea, cocoa), mineral water, orange juice: decreased drug absorption

Patient monitoring

• Monitor for signs and symptoms of GI irritation, including ulcers.

• Monitor blood pressure.

• Evaluate blood calcium and phosphate levels.

Patient teaching

Tell patient to immediately report serious vomiting, severe chest or abdominal pain, difficulty swallowing, or abdominal swelling.

• Instruct patient to take tablets first thing in the morning on an empty stomach, with 6 to 8 oz of water only.

• Instruct patient to follow oral solution with at least 60 ml (2 oz) of water.

• Tell patient not to lie down, eat, drink, or take other oral medications for 30 minutes after taking dose.

• Advise patient to take only those pain relievers suggested by prescriber. Inform him that some over-the-counter pain medications (such as aspirin and NSAIDs) may worsen drug's adverse effects.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

Mentioned in ?
References in periodicals archive ?
Conclusion: Our study results suggest that alendronate sodium is a valuable treatment agent for osteoporosis in postmenopausal women.
Alendronate sodium develops fast after entering China, annual sales value rising from less than CNY 30 million in 2005 to CNY 121 million in 2014 and CAGR during this period reaching 18.14%.
Food and Drug Administration (FDA) approved alendronate sodium for treatment to increase bone mass in men with osteoporosis.
The effect of alendronate sodium on carotid artery intima-media thickness and lipid profile in women with postmenopausal osteoporosis.
Limited Tenders are invited for Supply Of Alendronate Sodium 35 Mg Tablet / Capsule
Limited Tenders are invited for Procurement of medicines out of echs dglp fund: Alendronate Sodium 35 Mg Tab, Alendronate Sodium 75mg Tab, Antiseptic Liquid 500 Ml, Betnovate C 30 Gm, Calcium Carbonate With Vit D3 500mg Tab, Dapsone 100 Mg Tab
40 Teva USA Alendronate Sodium 00093517144 $229,911,061
103 Barr Alendronate sodium 00555072054 $112,542,896
Tenders are invited for Alendronate Sodium Tab 70Mg
Contract awarded for alendronate sodium 2,026 igss code and / or alendronate, 70 mg tablet
Alendronate Sodium Tablets Teva Pharmaceuticals Fosamax Tablets